The current consensus rating on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is Buy with a consensus target price of $16.6667 per share, a potential 142.18% upside. Some recent analyst ratings include Business Description: Aurinia Pharmaceuticals Inc is a clinical stage pharmaceutical company. The firm is engaged in the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis. AUPH Description — Aurinia Pharmaceuticals Inc Aurinia Pharmaceuticals is a biopharmaceutical company engaged in the business of development and commercialization of therapeutic drugs. AUPH — Key Stats (updated Friday, May 29, 10:21 AM) Aurinia Pharmaceuticals (0UJF) share price, charts, trades & the UK's most popular discussion forums. Free forex prices, toplists, indices and lots more. 09/05/2020 10:28:57 Cookie Policy +44 (0) 203 8794 460 Free Membership Login
Aurinia Pharmaceuticals, Inc. (auph) 单位:美元 至2019-12-31: 至2018-12-31: 至2017-12-31: 至2016-12-31: 净收益 -1.24亿 -6,412.00万 -7,079.20万
Aurinia Pharmaceuticals Inc. AUPH Morningstar Rating Rating as of Jun 5, 2020. Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Operating Performance Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. View today's stock price, news and analysis for Aurinia Pharmaceuticals Inc. (AUP). Barron's also provides information on historical stock ratings, target prices, company earnings, market 股票名称 最新价 涨跌幅; 暂未登录，请先登录 . 公司资料. 更多 > 公司名称：Aurinia Pharmaceuticals Inc. 上市日期：2014-09-02: 注册地址:Alberta Canada: Find the latest SEC Filings data for Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) at Nasdaq.com. Aurinia Pharmaceuticals Has Lots of Upside Potential By Chris Lau, InvestorPlace Contributor Jul 13, 2018 Aurinia is a biotech firm whose primary goal is treating Lupus. We wouldn't blame Aurinia Pharmaceuticals Inc. shareholders if they were a little worried about the fact that Neil Solomons, the Chief Medical Officer recently netted about CA$1.3m selling shares at an average price of CA$21.01.That's a big dump, and it decreased their holding size by 22%, which is notable but not too bad. Check out our latest analysis for Aurinia Pharmaceuticals
提供Aurinia Pharmaceuticals Inc(AUPH)股票的行情走势、五档盘口、逐笔交易等实时行情数据，及Aurinia Pharmaceuticals Inc(AUPH)的资讯、公司公告、研究报告、行业研报、F10资料、行业资讯、资金流分析、阶段涨幅、所属板块、财务指标、机构观点、行业排名、估值水平、股吧互动等与Aurinia Pharmaceuticals Inc(AUPH 在 Yahoo 財經討論區查看最新的 Aurinia Pharmaceuticals Inc (AUPH) 股票討論內容。分享你的意見，並參考其他股票交易員和投資者的深入分析。 取得 Aurinia Pharmaceuticals Inc (AUPH) 的最新股票消息和頭條新聞，助你作出交易和投資決策。 Aurinia制药的新闻 美股异动 | 治疗狼疮新药实验数据良好，临床生物制药公司Aurinia(AUPH.US)盘前涨逾100%. 智通财经APP获悉，周四(12月5日)，临床生物制药公司Aurinia Pharmaceuticals(AUPH.US)宣布了治疗狼疮常见并发症新药voclosporin第三阶段试验的积极疗效和安全性数据良好。
TG治疗公司TG Therapeutics, Inc.(NASDAQ:TGTX)创立于1993年，总部位于美国纽约州纽约市，全职雇员105人，是一家生物制药公司，为慢性淋巴细胞白血病（CLL），非霍奇金淋巴瘤（NHL）和多发性硬化症（MS）患者开发和提供药物。 TG治疗TG Therapeutics, Inc